S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The gold catalyst we’ve waited for (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The gold catalyst we’ve waited for (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Urgent Warning (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The gold catalyst we’ve waited for (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The gold catalyst we’ve waited for (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Urgent Warning (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The gold catalyst we’ve waited for (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The gold catalyst we’ve waited for (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Urgent Warning (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The gold catalyst we’ve waited for (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The gold catalyst we’ve waited for (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Urgent Warning (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
NASDAQ:RLAY

Relay Therapeutics - RLAY Stock Forecast, Price & News

$15.58
-0.05 (-0.32%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.38
▼
$16.40
50-Day Range
$15.33
▼
$22.76
52-Week Range
$12.65
▼
$35.36
Volume
694,652 shs
Average Volume
1.02 million shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.63

Relay Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
103.0% Upside
$31.63 Price Target
Short Interest
Bearish
21.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.13 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.01) to ($3.08) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.19 out of 5 stars

Medical Sector

958th out of 983 stocks

Biological Products, Except Diagnostic Industry

161st out of 163 stocks

See Top Rated MarketRank™ Stocks Here

RLAY stock logo

About Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Stock News Headlines

March 13, 2023 | americanbankingnews.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $32.14 Average PT from Analysts
March 6, 2023 | finance.yahoo.com
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
March 22, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 1, 2023 | msn.com
Relay Therapeutics's Return On Capital Employed Overview
February 26, 2023 | finance.yahoo.com
Relay Therapeutics Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
February 23, 2023 | finance.yahoo.com
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates
February 23, 2023 | msn.com
Relay Therapeutics GAAP EPS of -$0.56 beats by $0.14, revenue of $0.25M beats by $0.08M
February 22, 2023 | benzinga.com
Relay Therapeutics Earnings Preview
March 22, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
February 16, 2023 | finance.yahoo.com
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 15, 2023 | seekingalpha.com
RLAY Relay Therapeutics, Inc.
February 7, 2023 | finance.yahoo.com
Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight
February 2, 2023 | finance.yahoo.com
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 1, 2023 | nasdaq.com
BlackRock Increases Position in Relay Therapeutics (RLAY)
January 15, 2023 | nasdaq.com
Relay Therapeutics (RLAY) Shares Cross Above 200 DMA
January 13, 2023 | finance.yahoo.com
Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
December 31, 2022 | finance.yahoo.com
Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Intrinsic Value Is Potentially 23% Below Its Share Price
November 30, 2022 | msn.com
Relay Therapeutics: No. 1 on the list of large employers in Massachusetts for 2022
November 24, 2022 | finance.yahoo.com
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
November 7, 2022 | markets.businessinsider.com
Where Relay Therapeutics Stands With Analysts
November 3, 2022 | finance.yahoo.com
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 3, 2022 | finance.yahoo.com
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
November 2, 2022 | msn.com
Relay Therapeutics's Earnings Outlook
October 14, 2022 | finance.yahoo.com
Relay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 11% this week, taking one-year losses to 44%
September 30, 2022 | markets.businessinsider.com
5 Analysts Have This to Say About Relay Therapeutics
September 30, 2022 | markets.businessinsider.com
Expert Ratings for Relay Therapeutics
September 26, 2022 | nasdaq.com
Relay Therapeutics Breaks Above 200-Day Moving Average - Bullish for RLAY
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Company Calendar

Last Earnings
2/23/2023
Today
3/22/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLAY
CUSIP
N/A
CIK
1812364
Web
www.relaytx.com
Phone
617-370-8837
Fax
N/A
Employees
245
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.63
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+103.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-290,510,000.00
Net Margins
-21,036.13%
Pretax Margin
-21,036.13%
Return on Equity
-33.05%
Return on Assets
-28.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.00
Quick Ratio
16.00

Sales & Book Value

Annual Sales
$1.38 million
Price / Sales
1,370.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.86 per share
Price / Book
1.98

Miscellaneous

Outstanding Shares
121,390,000
Free Float
116,008,000
Market Cap
$1.89 billion
Optionable
Not Optionable
Beta
1.32

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Co-Founder & Independent Chairman
    Comp: $105k
  • Dr. Sanjiv K. Patel M.A. (Age 49)
    M.B.A., M.D., MBBS, CEO, Pres & Director
    Comp: $1.02M
  • Dr. Mark Murcko Ph.D. (Age 63)
    Co-Founder & Director
    Comp: $65.75k
  • Mr. Thomas CatinazzoMr. Thomas Catinazzo (Age 46)
    Chief Financial Officer
    Comp: $558.69k
  • Mr. Andy PorterMr. Andy Porter
    Chief Admin. Officer
  • Mr. Brian R. Adams J.D. (Age 49)
    Chief Legal Officer & Sec.
    Comp: $612.05k
  • Dr. Donald A. Bergstrom M.D.Dr. Donald A. Bergstrom M.D. (Age 51)
    Ph.D., Pres of R&D
    Comp: $722.26k
  • Mr. Peter Rahmer
    Sr. VP of Corp. Affairs & Investor Relations
  • Dr. Deborah Palestrant Ph.D.
    VP of Corp. Devel. & Strategy
  • Mr. Jim Watters Ph.D.
    Sr. VP & Head of Late Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RLAY Stock - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLAY shares.
View RLAY analyst ratings or view top-rated stocks.

What is Relay Therapeutics' stock price forecast for 2023?

7 brokers have issued 1 year price objectives for Relay Therapeutics' shares. Their RLAY share price forecasts range from $13.00 to $46.00. On average, they predict the company's share price to reach $31.63 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts.

How have RLAY shares performed in 2023?

Relay Therapeutics' stock was trading at $14.94 at the beginning of the year. Since then, RLAY shares have increased by 4.3% and is now trading at $15.58.
View the best growth stocks for 2023 here.

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our RLAY earnings forecast.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) released its quarterly earnings results on Thursday, February, 23rd. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.12. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $0.18 million. Relay Therapeutics had a negative trailing twelve-month return on equity of 33.05% and a negative net margin of 21,036.13%. The business's revenue for the quarter was down 55.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.36 earnings per share.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), First Trust NASDAQ BuyWrite Income ETF (FTQI), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

(RLAY) raised $250 million in an initial public offering on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Relay Therapeutics' stock symbol?

Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY."

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.72%), JPMorgan Chase & Co. (3.70%), ArrowMark Colorado Holdings LLC (2.22%), Morgan Stanley (1.96%), T. Rowe Price Investment Management Inc. (1.66%) and Norges Bank (1.48%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Rock Ventures Iii LP Third, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends.

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relay Therapeutics' stock price today?

One share of RLAY stock can currently be purchased for approximately $15.58.

How much money does Relay Therapeutics make?

Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.89 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Relay Therapeutics have?

The company employs 245 workers across the globe.

How can I contact Relay Therapeutics?

Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com.

This page (NASDAQ:RLAY) was last updated on 3/22/2023 by MarketBeat.com Staff